DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
October 04, 2024
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
The Cravath team is led by partners Cole DuMond and Daniel J. Cerqueira and includes associates Jason O. Rooindej and Alexander J.A. Burger on M&A matters; partner David J. Kappos, of counsel Kathryn‑Ann Stamm and associate Kenya Rowser on intellectual property matters; partner Nicholas A. Dorsey on financing matters; partner Christopher K. Fargo, of counsel Kiran Sheffrin and associate Josh Banafsheha on tax matters; and partner George E. Zobitz and of counsel Alexander Gerten on financial restructuring and reorganization matters. Abby Baskin also worked on M&A matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2016, University of Pennsylvania Law Schoolcum laude
-
B.S., 2013, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 2013, Harvard Law Schoolmagna cum laude
-
B.A., 2010, Cornell UniversityPhi Beta Kappa
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 2009, Cornell Law SchoolOrder of the Coif, summa cum laude
-
M.Acc., 2006, Case Western Reserve Universitysumma cum laude
-
B.S., 2006, Case Western Reserve Universitysumma cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2006, Columbia Law SchoolHarlan Fiske Stone; Michael Lynne Scholar
-
B.A., 2003, Boston CollegeHonors Program, cum laude
- New York
Education
Admitted In
-
J.D., 1995, New York University School of Lawwith Honors, cum laude
-
B.A., 1991, Franklin & Marshall College
- New York
Education
Admitted In
- Photo
-
-
J.D., 2016, Cornell Law School
-
LL.M., 2016, City University of Hong Kong
-
Master II, 2016, University Paris 1 Pantheon-Sorbonne
-
Master I, 2013, University Paris 1 Pantheon-Sorbonne
-
LL.B., 2013, University Paris 1 Pantheon-Sorbonne
-
LL.B., 2013, King's College LondonFirst Class Honors.
- New York
Education
Admitted In
- Photo
-
-
J.D., 2013, Brooklyn Law Schoolmagna cum laude
-
B.A., 2010, Wesleyan University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
September 30, 2025
Future Standard’s Acquisition of Post Road Group’s Digital Infrastructure Platform
On September 30, 2025, Future Standard, a global alternative asset manager, announced it has entered into an agreement to acquire the Digital Infrastructure platform of Post Road Group, an alternative investment advisory firm. The platform specializes in credit and structured equity investments across digital infrastructure assets, including data centers, fiber networks and cloud connectivity. Cravath is representing Future Standard in connection with the transaction.
Deals & Cases
September 22, 2025
Premier’s $2.6 Billion Acquisition by Patient Square
On September 22, 2025, Premier, Inc. (“Premier”), a leading technology‑driven health care improvement company, announced that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital (“Patient Square”) in a transaction valued at $2.6 billion. Under the terms of the agreement, which has been unanimously approved by Premier’s Board of Directors, Premier stockholders will receive $28.25 in cash per share. Cravath is representing the Transaction Committee of Premier’s Board of Directors in connection with the transaction.
Deals & Cases
August 15, 2025
Fitch Learning’s Acquisition of Moody’s Analytics Learning Solutions and the Canadian Securities Institute
On August 14, 2025, Fitch Learning, a global leader in financial learning and professional certifications, announced it signed an agreement with Moody’s to acquire two of their businesses, Moody’s Analytics Learning Solutions, a global provider of credit training, and the Canadian Securities Institute, a leading provider of professional certifications for the Canadian financial services industry. Cravath is representing Fitch Learning in connection with the transaction.
Deals & Cases
August 11, 2025
Intermex’s Acquisition by Western Union
On August 10, 2025, International Money Express, Inc. (“Intermex”) and The Western Union Company (“Western Union”) announced they have entered into a definitive agreement under which Western Union will acquire Intermex in an all‑cash transaction at $16.00 per share, representing a total equity and enterprise value of approximately $500 million. Cravath is representing Intermex’s Strategic Alternatives Committee in connection with the transaction.
